DiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference on March 18-19, 2019
March 12 2019 - 1:00PM
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it
will be attending the 31st Annual ROTH Conference March 18-19,
2019, at The Ritz Carlton, Laguna Niguel in Dana Point, CA.
DiaMedica’s President and CEO, Rick Pauls, will be hosting
one-on-one meetings with institutional investors at the conference
and attendees can contact their Roth Capital Partners
representative to arrange a meeting.
About DiaMedica Therapeutics
Inc.
DiaMedica Therapeutics Inc. is a clinical stage
biopharmaceutical company focused on developing novel treatments
for chronic kidney diseases and neurological disorders. The Company
currently has an ongoing phase II study in acute ischemic stroke
and a phase Ib study in chronic kidney disease. DiaMedica’s shares
are listed on The Nasdaq Capital Market under the trading symbol
“DMAC.”
For more information, please visit
www.diamedica.com. Contact:
Scott KellenChief Financial OfficerPhone: (763)
496-5118 skellen@diamedica.com
Paul Papi Vice President of Business Development
Phone: (617) 899-5941 info@diamedica.com
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024